News | Cardiac Diagnostics | August 24, 2018

NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial

Agency will cease funding for study of effects of one daily serving of alcohol on cardiovascular health due to concerns about credibility of study design

NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial

August 24, 2018 — The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular Health (MACH) trial. The decision is based on concerns about the study design that cast doubt on its ultimate credibility. This includes whether the study would effectively address other significant consequences of moderate alcohol intake, such as cancer.

National Institute of Alcohol Abuse and Alcoholism (NIAAA) funding for the MACH trial will end within the next few months following completion of an orderly closeout. The decision to end funding is informed by recommendations of the Advisory Committee to the Director (ACD).

The MACH study was designed as a multicenter, randomized clinical trial to determine the effects of one serving of alcohol (approximately 15 grams) daily, compared to no alcohol intake, on the rate of new cases of cardiovascular disease and the rate of new cases of diabetes among participants free of diabetes at baseline. The study was launched because some epidemiological studies have shown that moderate alcohol consumption has health benefits by reducing risk for coronary artery disease, type 2 diabetes and rheumatoid arthritis.  A multi-site randomized trial often is the best way to establish the evidence base about the benefits versus the risks of an intervention like moderate alcohol intake. The study aimed to enroll 7,800 participants. After a planning phase, it began enrollment on Feb. 5, 2018, and was suspended on May 10, 2018, at which time there were 105 participants enrolled in the study.

The recommendations, based on findings of an ACD working group, also noted that significant process irregularities in the development of the funding opportunities for the MACH funding awards undermined the integrity of the research process. Additionally, a preliminary report from the NIH Office of Management Assessment (OMA) determined that a small number of NIAAA employees violated NIH policies in soliciting gift funding and circumvented standard operating procedures designed to ensure a fair competition for NIH funding. These policy violations were committed by NIAAA employees prior to the involvement of the Foundation for the National Institutes of Health (FNIH), and the review found that the FNIH conducted its role appropriately. The FNIH manages the solicitation of funds by private donors for NIH research projects with appropriate firewalls.

NIH will take appropriate personnel actions, but cannot comment on specific personnel matters.

“NIH has strong policies that detail the standards of conduct for NIH employees, including prohibiting the solicitation of gifts and promoting fairness in grant competitions.  We take very seriously any violations of these standards,” said NIH Director Francis S. Collins, M.D., Ph.D., who tasked reviews by OMA and the ACD when informed of the allegations.

NIH will voluntarily share the OMA and ACD reports with the HHS Office of Inspector General.

NIH is determined to make sure that such violations of policies are not happening in other parts of the agency. Consistent with the ACD recommendations, NIH is taking the following immediate actions:

  • Each NIH institute, center and office is conducting a thorough review of processes and practices of programmatic interactions with potential applicants;
  • NIH will explore additional measures to identify any instances of:
    • Employee solicitation of external funding;
    • Inappropriate engagement by NIH employees, contractors, etc., with current or potential NIH awardees that could influence administration of NIH research programs; and
    • Inappropriate external influence on the administration of NIH research programs.

The MACH trial is led by Beth Israel Deaconess Medical Center, Boston. Collaborators are:

  • The Center for Bioethics and Research, Nigeria;
  • Harvard School of Public Health, Boston;
  • IDIBAPS, Spain;
  • Johns Hopkins University, Baltimore;
  • University of Copenhagen, Denmark;
  • Wake Forest University Health Sciences, Winston-Salem, N.C.; and
  • Julius Center, Netherlands.  

The trial is funded in part by NIAAA, which expected to commit $20 million to the overall project over 10 years, of which $4 million has been spent. It is also funded in part by private donations of $67.7 million raised to date by the FNIH, of which $11.8 million has been spent.  

“The integrity of the NIH grants administrative process, peer review, and the quality of NIH-supported research must always be above reproach,” added Collins.  “When any problems are uncovered, however, efforts to correct them must be swift and comprehensive.”

For more information:


Related Content

Sedentary Lifestyle Cancels Out Heart Benefits of Normal Weight
News | Cardiac Diagnostics | January 09, 2019
January 9, 2019 — Researchers at the University of Florida have found that low levels of physical activity can put he
Livongo Launches Applied Health Signals Product Category
News | Cardiac Diagnostics | November 30, 2018
Healthcare technology company Livongo recently announced the launch of its Applied Health Signals product category,...
HHS Releases Second Edition of Physical Activity Guidelines for Americans. #AHA2018 #AHA18
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
Overlay Init